Loading

Hereditary Spherocytosis (Spherocytic Anemia)

Date of document July 2022
This is the current valid version of the document

1Summary

Hereditary spherocytosis (HS) belongs to the group of hemolytic anemias. It is caused by different mutations in the genes for α-spectrin, β-spectrin, ankyrin-1, band 3 or protein 4.2. The majority of mutations are inherited in an autosomal dominant manner. They lead to a loss of cohesion between the membrane skeleton and the lipid layer. Due to the altered erythrocyte deformability, the erythrocytes are increasingly degraded in the spleen.

The clinical manifestation is highly variable and ranges from asymptomatic courses to clinically relevant hemolysis symptoms. There is no causal therapy. In many patients, an observational approach is indicated. The most effective therapy is splenectomy. In symptomatic patients, partial or total splenectomy is recommended.

2Basics

2.1Definition and basic information

Hereditary spherocytosis (HS) is a heterogeneous group of disorders of erythrocytes. The common denominator are structural membrane defects that lead to changes in erythrocyte deformability. The very variable clinical expression is due to the different mutations of the membrane protein genes, the different functional effects and the respective mode of inheritance.

The clinical picture was first described in the second half of the 19th century. In 1900, Oskar Minkowski published his observations on familial clustering [1]. Hereditary spherocytosis belongs to the congenital hemolytic anemias, the name is due to the microscopic aspect of spherical cells in the blood smear.

2.2Epidemiology

The prevalence is estimated to be about 1:2,500 - 5,000 in Germany, exact numbers are not available [2]. Hereditary spherocytosis is by far the most common congenital hemolytic anemia in individuals with a northern or central European background, but belongs to the rare diseases [3].

2.3Pathogenesis

Common causes of the various forms of hereditary spherocytosis are defects in the proteins of the erythrocyte membrane. As a result, the cohesion with the lipid bilayer is disturbed, and the surface area and deformability of the erythrocytes are progressively reduced. One of the consequences is accelerated degradation of the dysfunctional erythrocytes in the spleen. In hereditary spherocytosis, the genes for the membrane proteins ankyrin, band 3, and spectrin are most commonly affected [45]. Less common are alterations in the genes of protein 4.2, the Rh complex, and cases in which the protein defect is not definable. In about 75% of affected individuals, the disease is inherited in an autosomal dominant manner. In the remaining patients, recessive inheritance or new mutations are present. A classification based on the molecular basis is shown in Table 1 [4567].

Table 1: Molecular classification of hereditary spherocytosis. 

Protein

Gene

Frequency1

Inheritance2

Progress form3

OMIM4

Ankyrin-1

ANK1

40 - 65%

autosomal dominant

 

mostly moderate; rarely light or heavy

#182900

α Spectrin,

SPTA1

< 5%

autosomal recessive

mostly light,

rarely severe with biallelic mutations

#270970

β Spectrin,

SPTB

15 - 30%

autosomal dominant

 

easy to medium

#182870

Gang 3

SLC4A1

20 - 35%

autosomal dominant

easy to moderate;

very rarely severe recessive form

#109270

Protein 4.2

EPB42

< 5%

autosomal recessive

easy to medium

#612690

1 Frequency - relative frequency in Central Europe;
2 related to monoallelic forms;
3 progression form - see Table 2;
4 OMIM - Online Mendelian Inheritance in Man [8].

The spectrum of mutations in affected genes is diverse: splicing, skipping, missense, nonsense, deletion, frameshift, polymorphisms [78910]. Many genetic aberrations are 'personal', i.e. specific to the affected family [111213]. The clinical picture of HS within a family is often very similar.

3Prevention and screening

Screening of asymptomatic newborns is not established. In children of patients with dominantly inherited HS, special attention should be paid to hemolysis symptoms [214].

4Clinical picture

4.1Symptoms

The clinical spectrum of hereditary spherocytosis ranges from severe cases requiring transfusion already in childhood to asymptomatic patients with incidental diagnosis in old age on the occasion of a laboratory examination for other indications. The characteristic findings and typical complications are summarized in Tables 2 and 3.

Table 2: Characteristic findings in hereditary spherocytosis 

Symptom

Note

Anemia

Coombs negative

Icterus

indirect bilirubin increased

Splenomegaly

variable level

Family history

positive in most patients (75%)

Table 3: Typical complications of hereditary spherocytosis 

Symptom

Note

Cholelithias

due to chronic hemolysis

aplastic crisis

most frequently after first time infection with parvovirus B19

hemolytic crisis

after intercurrent infections

megaloblastic crisis

in patients with folic acid deficiency

Hemolytic crises occur repeatedly, especially in the context of intercurrent infections. The course is usually mild in young adults and blood transfusion is not required. The aplastic crisis is usually unique. It may result in a severe drop in hemoglobin concentration, requiring blood transfusion. Cardiovascular complications, extramedullary hematopoiesis, or secondary hemochromatosis are rare [515]. Before making the diagnosis of secondary hemochromatosis in HS, primary causes such as HFE-associated hereditary hemochromatosis must be excluded. Hemolytic crises occur repeatedly, especially in the setting of intercurrent infections. The course is usually mild in young adults and blood transfusion is not required.

The chronically increased hemolysis can lead to extramedullary hematopoiesis with the clinical picture of intrathoracic, paravertebral tumors even in patients with a mild form of progression - who were not splenectomized - after decades of progression. Leg ulcers may occur in elderly patients.

A classification of hereditary spherocytosis based on clinical severity can be found in Table 4 [21116].

Table 4: Clinical classification of hereditary spherocytosis  

Carrier

easy

moderately difficult

heavy

Very heavy

Patients (%)1

25 - 30

60 - 70

10

3 - 5

Hemoglobin (g/L)

normal

11 - 15

8 - 11

6 - 8

< 6

Reticulocytes (%)

1 - 4

< 6

≥ 6

> 10

> 10

Bilirubin (mg / dL)

< 1

1 - 2

≥ 2

≥ 2 - 3

≥ 3

Blood smear

normal, occasionally isolated spherocytes

isolated spherocytes

spherocytes detectable

spherocytes detectable

microspherocytes

poikilocytosis

Transfusion requirements

no

0 - 1

0 - 2

≥ 3

regularly

1 Relative frequency (%);
2 osmotic fragility;

4.2Asymptomatic persons with abnormal laboratory parameters

A special group are carriers (adults without clinical symptoms and without a positive family history) in whom abnormal laboratory parameters were found by chance. Evidence of hereditary spherocytosis is summarized in Table 5 [16]:

Table 5: Laboratory evidence of hereditary spherocytosis 

Parameter

Comments

MCHC above the normal limit (35 or 36 g/dl)*.

a high specificity has the combination of MCHC above the normal limit

and RDW >15%;

In abortive mild forms, however, RDW values are rarely increased

Reticulocytes increased

may occur intermittently

Spherocytes

single

LDH increased

Indirect bilirubin increased

rare

Haptoglobin decreased

occasionally also normal in asymptomatic individuals

Multiplication of hyperchromic, hyperdense erythrocytes

especially in moderate and severe spherocytosis

slight increase in osmotic fragility

in the particularly sensitive test methods (AGLT)

decreased binding of eosin-5-malemide (band 3) to the erythrocyte membrane

EMA test pathological

* see chapter 4.3 for a more detailed presentation of the parameter MCHC

The combination of several parameters confirms the suspected diagnosis of a predisposition for HS. If no spherocytes are detectable, no changes in indices are present, and reticulocytes are normal, hereditary spherocytosis cannot be ruled out, but it is unlikely that this individual will become symptomatic. Differentiation between a clinically asymptomatic predisposition and a mild form of spherocytosis can be difficult. Occasionally, mild forms may exacerbate in splenomegaly of other etiologies (e.g., lymphoma) or in viral infections (EBV, parvovirus).

4.3MCHC as an indicator of erythrocyte membrane disease

The increased MCHC value (Mean Cellular Hemoglobin Concentration) has a special significance in the identification of spherocytosis patients. It measures the hemoglobin concentration in hemoglobin per 100 ml erythrocytes.

Increased MCHC levels may be due to medical, but also to technical reasons:

  • hemoglobin level determined too high in case of plasma opacities of any kind

  • erythrocyte count determined too low, e.g. in the case of coagulated blood

  • high titre cold agglutinins

  • hereditary membrane disorders of erythrocytes as in hereditary spherocytosis and variants such as xerocytosis

  • hemoglobin CC abnormality

  • homozygous sickle cell disease (occasionally)

  • hemochromatosis patients with massive iron overload [15], also depending on genotype.

5Diagnosis

5.1Diagnostics for suspected hereditary spherocytosis

The diagnostic steps in adults are shown in Tables 6 and 7 and as an algorithm in Figure 1.

Table 6: Basic diagnostics for suspected hereditary spherocytosis and evaluation of diagnostic criteria 

Parameter

(mandatory)

Specification

Evaluation

(as a diagnostic criterion)

Family history

  • autosomal dominant or recessive

  • optional

Splenomegaly

  • Physical examination

  • Ultrasound

  • optional

Blood count automatically

  • Anemia

  • MCHC1 > 35 g/dl

  • Anisocytosis (RDW2 )

  • optional

  • optional

  • optional

Blood count microscopic

  • Spherocytes

  • Anisocytosis

  • variable3, 4

  • optional

increased hemolysis

  • Reticulocytes increased or normal

  • low percentage of immature reticulocytes

  • Indirect bilirubin increased

  • LDH5 increased

  • Haptoglobin not detectable

  • at least 2 parameters mandatory

Coombs test

  • negative

  • mandatory

1 MCHC - mean corpuscular hemoglobin concentration;
2 RDW- size distribution of erythrocytes in automatic blood count;
3 detectable only in perfect smears;
4 microscopic picture may be uncharacteristic in adults; few or no spherocytes may be detectable in mild forms, while polychromasia and anisocytosis are almost always seen;
5 LDH - lactate dehydrogenase;

Table 7: Further diagnostics for suspected hereditary spherocytosis 

Parameter

Specification

Osmotic fragility

Acidified Glycerol Lysis Time (AGLT)

Flow cytometry

Eosin-5-maleimide binding

Ektacytometry

  • currently not available in Germany

  • available in Switzerland

Membrane analysis

SDS PAGE

Gene analysis

Sequencing of candidate genes: linkage analysis

There is no single test that detects all forms of hereditary spherocytosis and reliably differentiates them from other forms of membrane-related hemolytic anemias [161718192021]. Therefore, examination with two test methods is recommended. Sensitivity of up to 100% can be achieved in the combination of AGLT and EMA test [18]. The examination of osmotic resistance with hypotonic salt solutions has a significantly lower sensitivity than AGLT and EMA test.

5.1.1Acidified Glycerol Lysis Time (AGLT)

The AGLT test measures the time to 50% hemolysis of a blood sample in a hypotonic saline/glycerol solution. Determination of hemolysis time with the Acidified Glycerol Lysis Time (AGLT) has high specificity, with sensitivity ranging from 80 to 95% [22]. The test must be performed within hours of blood collection or on samples sent by express mail (cooled shipping depending on the season)! It can also be positive in patients with acquired hemolytic anemia, chronic renal failure, or myelodysplastic syndrome [19].

5.1.2Flow cytometry (eosin-5-maleimide test)

The flow cytometric method (EMA test) was introduced in 2000 [23]. It is based on the decreased binding of the fluorescent dye eosin-5-maleimide in patients with hereditary spherocytosis compared to normal subjects. Sensitivity is 90 - 95%, specificity is 95 - 99%. Maximum delay between blood collection and test performance may not exceed 48 hrs. In hereditary pyropoikilocytosis the fluorescent dye is bound even less than in hereditary spherocytosis, in stomatocytosis the binding is increased [17]. The binding of eosin-5-maleimide may also be decreased in patients with congenital dyserythropoietic anemia type II (CDA type II).

5.1.3Ektacytometry

Precise characterization of osmotic fragility (and differentiation between spherocytosis and macrocytic stomatocytosis) is possible by means of osmotic gradient ektacytometry; however, this procedure is currently available in only a few laboratories and not in all countries. Since the examination can only be done in fresh blood samples taken at the site of examination, ektacytometry is reserved for a few exceptional cases in which the diagnosis cannot be clarified otherwise.

5.1.4Membrane Analysis

Biochemical analysis by gel electrophoresis can be used quantitatively to detect the decreased membrane proteins and qualitatively to identify the affected proteins. It rarely contributes to diagnostics.

5.1.5Genetic Analysis

Molecular genetic diagnostics identifies the patient- or family-specific genetic defect [9]. Due to the numerous target genes with the heterogeneity of possible mutations as well as the associated considerable costs, it is reserved for special cases in which a therapeutic consequence results from the diagnosis.

With all diagnostic methods, there are false positive and / or false negative results. Therefore, the diagnosis in individuals without a positive family history should generally not be based on one method, e.g., osmotic resistance only or EMA only or biochemical membrane diagnostics only. At least 2 different methods should be used. Also, future, diagnostic tests will have to be compared in their specificity and sensitivity with these laboratory methods.

Figure 1: Diagnostic algorithm for suspected hereditary spherocytosis 
1 characteristic symptoms - anemia, icterus, splenomegaly, hemolytic or aplastic crisis after viral infection;
2 abnormal laboratory findings - MCHC > 35 and RDW > 15 %; reticulocytes increased, hemolysis parameters positive;
3 Basic diagnostics - physical examination; CBC with microscopic differentiation of erythrocytes, reticulocytes, LDH, bilirubin, haptoglobin, direct Coombs test;
4 osmotic fragility - see chapter 5. 1. 1.
5 flow cytometric assay for dye binding, see chapter 5. 1. 2.
6 ektacytometry - see text chapter 5. 1. 3.

5.2Differential diagnosis

The differential diagnosis in adult patients with hyperregenerative normochromic anemia and spherocytes includes:

5.2.1Hereditary

Hereditary elliptocytosis [67]: Findings of the basic diagnostics are largely identical to those of hereditary spherocytosis, but the osmotic fragility of erythrocytes is usually increased only in moderate to severe cases. The leading diagnostic procedure is the microscopic analysis of the blood smear with identification of elliptocytes. This also applies to spherocytic elliptocytosis, in which spherocytes are found in addition to elliptocytes.

Hereditary pyropoikilocytosis: Caused by homozygosity for spectrin abnormalities with a positive family history for hereditary elliptocytosis. Flow cytometric analysis (EMA test) shows clearly decreased binding of the dye as in HS. Crucial are the blood smear and a pronounced reduction of the MCV to values below 70 fl, in contrast to other membranopathies.

Hereditary defects of erythrocyte membrane cation permeability: differential diagnosis is summarized in Table 8 [672425].

Table 8: Hereditary defects of the cation permeability of the erythrocyte membrane [modified from 24] 

Stomatocytosis with cellular hyperhydration

Cryohydrocytosis

Familial pseudohyperkalemia

Xerocytosis

Hemolysis

moderate to severe

mild to moderate

mild to normal

mild to moderate

MCV

(80 - 100 fl)

110 – 150

90 - 105

82 - 104

84 - 122

MCHC

(32 – 36 g/dL)

24 – 30

34 - 38

33 - 39

34 - 38

Erythrocytic Na+/K+ (95-110 mmol/L Ery)

110 – 140

75 - 105

87-109

75-99

Osmotic fragility

Extremely increased

Normal to slightly increased

Slightly decreased

Decreased

Intrauterine ascites

no

no

no

Low to strong

Response to splenectomy

high risk of complications

bad

Splenectomy not required

bad

MCV - mean corpuscular volume; MCHC - mean hemoglobin concentration;

Hereditary stomatocytosis: The blood smear is crucial in this very rare clinical picture. Differentiation is important because splenectomy is often ineffective and associated with increased risk of thromboembolism. After storage of the blood sample at 40 C for 2 hours, serum potassium and MCV increase, MCHC normalizes.

Hereditary xerocytosis (formerly also dehydrated hereditary stomatocytosis): Largely unremarkable blood count, only rarely stomatocytes and echinocytes (especially in phase contrast microscopy). Osmotic fragility is slightly decreased. Patient history shows frequent intrauterine hydrops with ascites. Splenectomy is not effective and contraindicated due to increased risk of thromboembolism.

Congenital dyserythropoietic anemia type II: Although single spherocytes are also detectable in the smear, it shows marked poikilocytosis, almost always with basophilia. The reticulocyte count is often normal, but always not adequately increased in relation to the anemia. In case of doubt, detection of dyserythropoiesis in bone marrow aspirate is required for definite differentiation. The diagnosis is confirmed by the detection of the mutation of the SEC23B gene.

Other forms of congenital hemolytic anemia: Hereditary enzyme defects or structural defects of the hemoglobin genes also cause hemolytic anemia. Often, microscopic differential blood count can guide further diagnosis.

5.2.2Acquired

  • Autoimmune hemolytic anemia, especially the rare forms with a negative direct Coombs test

  • Microangiopathic hemolytic anemia

  • Hemolytic - uremic syndrome

  • Hypophosphatemia

  • (Delayed) hemolytic transfusion reaction

  • Hemolysis of toxic or infectious origin

6Therapy

There is no causal therapy for the genetic defect. The most effective symptomatic therapy is splenectomy. In symptomatic cholelithiasis, cholecystectomy is indicated [1626].

6.1Splenectomy

Splenectomy often leads to reduction of anemia and regression of increased hemolysis parameters. The changes in the smear, on the other hand, usually become more obvious than before. The indication for splenectomy is usually given in childhood, but if possible not performed before school age [2]. However, it must also be considered in adulthood depending on the clinical findings [1626]. Splenectomy is also an option in adults with extramedullary hematopoiesis. Whether extramedullary hematopoiesis subsequently regresses is an open question.

If hemolysis persists after splenectomy, the diagnosis must be questioned again, a search must be made for an accessory spleen and this needs to be removed if necessary. The indication for splenectomy depends on the clinical severity, see Table 9 [216].

Table 9: Indications for splenectomy 

Severity

Recommendation

Mild

usually not required

Moderate

  • In case of multiple hemolytic crises

  • with >2 transfusions in the last years

  • with pronounced reduction in performance

  • In symptomatic/painful splenomegaly with associated thrombocytopenia or leukocytopenia that affects the patient*s quality of life.

  • In severe jaundice leading to social problems; increased jaundice in the presence of concomitant Gilbert's syndrome.

Severe and very severe

all patients

The risk of splenectomy lies in the surgical procedure and the lifelong increased rate of severe infections, mainly due to pneumococci with a mortality of 0.1-0.4% [227]. This risk is reduced by subtotal rather than total splenectomy [2829], thus the former procedure should be preferred. Most data on subtotal splenectomy are from children, not adults. In an analysis of the Splenectomy in Congenital Hemolytic Anemia Consortium Registry, the mean hemoglobin increase was higher after total splenectomy than after partial splenectomy (4.2 g/dl vs 2.4 g/dl, p<0.001) [30].

Laparoscopic splenectomy is an alternative for hereditary spherocytosis. It is safe [303132]. However, to date, it is unclear whether laparoscopic partial resection is equivalent to open, subtotal splenectomy in terms of hematologic outcome and risk of recurrence.

Mild hemolysis with anemia may persist in patients with a severe course, especially with spectrin defects. In splenectomy, recommendations for vaccination and / or antibiotic prophylaxis must be followed.

7[Kapitel nicht relevant]

8Follow-up

8.1Controls in asymptomatic patients

There are no studies on the effectiveness of regular controls. Blood count analyses should be performed on an as-needed basis, especially in cases of anemia symptoms in temporal relation to infections. Because of the rare iron overload in moderate and severe forms, serum ferritin control is recommended at annual intervals. On the occasion of these controls, the vitamin B12 and folic acid levels should also be checked due to the increased need. Ultrasound of the bile ducts and spleen size is recommended at least every three years.

8.2Genetic counseling

If the patient wishes to have children, family counseling with examination of the partner for erythrocytic membranopathy is recommended.

9References

  1. Minkowski O: Über eine hereditäre, unter dem Bilde eines chronischen Ikterus mit Urobilinurie, Splenomegalie und Nierensiderosis verlaufende Affection. Verh Dtsch Kongr Inn Med 18:316-319, 1990

  2. S1-Leitlinie Hereditäre Sphärozytose 2016, 025-018. https://www.awmf.org/uploads/tx_szleitlinien/025-018l-s1_hereditaere-sphaerozytose_2016-12

  3. Orphanet, das Portal für seltene Erkrankungen. https://www.orpha.net/

  4. Delaunay J: The molecular basis of hereditary red cell membrane disorders. Blood Reviews 21:1-20, 2007. DOI:10.1016/j.blre.2006.03.005

  5. Perrotta S, Gallagher PG, Mohandas N: Hereditary spherocytosis. Lancet 372:1411-1426, 2008. DOI:10.1016/S0140-6736(08)61588-3

  6. Mohandas N: Inherited hemolytic anemia: a possessive beginner’s guide. Hematology Am Soc Hematol Educ Program 2018:377-381, 2018. DOI:10.1182/asheducation-2018.1.377

  7. Iolascon A, Andolfo I, Russo R: Advances in understanding the pathogenesis of red cell membrane disorders. Br J Haematol 187:13-24, 2019. DOI:10.1111/bjh.16126

  8. www.ncbi.nlm.nih.gov/omim

  9. He BJ, Liao L, Deng ZF et al.: Molecular Genetic Mechanisms of Hereditary Spherocytosis: Current Perspectives. Acta Haematol 139:60-66, 2018. DOI:10.1159/000486229

  10. Fattizzo B, Giannotta JA, Cecchi N et al.: Confounding factors in the diagnosis and clinical course of rare congenital hemolytic anemias. Orphanet J Rare Dis 16:415, 2021. DOI:10.1186/s13023-021-02036-4

  11. Eber SW, Armbrust R, Schröter W. Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis. J Pediatr 117:409-416, 1990. PMID:2391596

  12. Cynober T, Mohandas N, Tchernia G: Red cell abnormalities in hereditary spherocytosis: relevance to diagnosis and understanding of the variable expression of clinical severity. J Lab Clin Med 128:259-269, 1996. PMID:8783633

  13. Mariani M, Barcellini W, Vercellati C et al.: Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. Haematologica 93:1310-1317, 2008. DOI:10.3324/haematol.12546

  14. Michaels LA, Cohen AR, Zhao H, et al. Screening for hereditary spherocytosis by use of automated erythrocyte indexes. J Pediatr 130:957-960, 1997. DOI:10.1016/s0022-3476(97)70283-x

  15. Barton JC, Bertoli LF, Rothenberg BE: Peripheral blood erythrocyte parameters in hemochromatosis: evidence for increased erythrocyte hemoglobin content. J Lab Clin Med 135: 96-104, 2000. PMID:16838333

  16. Bolton-Maggs PHB, Langer JC, Iolascon A et al.: Guidelines for the diagnosis and management of hereditary spherocytosis – 2011 update. Brit J Haematol 156:37-49,2011. DOI:10.1111/j.1365-2141.2011.08921.x

  17. Walensky LD, Mohandas N, Lux SE: Disorders of the blood cell membrane. In: Handin RI, Lux SE: Principles and practice of hematology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 1726-17444, 2003.

  18. Bianchi P, Fermo E, Vercellati C et al.: Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study on 150 patients grouped according to the molecular and clinical characteristics. Haematologica 97:516-523, 2012. DOI:10.3324/haematol.2011.052845

  19. King MG, Garcon L, Hoyer JD et al. for the International Council for standardization in Haematology: ICSH guidelines for the laboratory diagnosis of nonimmune hereditary red cell membrane disorders

  20. Farias MG. Advances in laboratory diagnosis of hereditary spherocytosis. Clin Chem Lab Med 55:944-948, 2017. DOI:10.1515/cclm-2016-0738

  21. Ciepiela O: Old and new insights into the diagnosis of hereditary shphreocytosis. Ann Transl Med 6:339-348, 2018. DOI:10.21037/atm.2018.07.35

  22. Eber SW, Pekrun A, Neufeldt A, Schröter W: Prevalence of increased osmotic fragility of erythrocytes in German blood donors: screening using a modified glycerol lysis test. Ann Hematol 64:88-92, 1992. PMID:1554800

  23. King MJ, Behrens J, Rogers C: Rapid flow cytometric test for the diagnosis of membrane cytoskeleton-associated haemolytic anaemia. Brit J Haematol 2000;111:924-933. DOI:10.1111/j.1365-2141.2000.02416.x

  24. Eber S in Hämolytische Anämien. Hrsg.: J. Schubert, H. Schrezenmeier, Röth. UNI-MED 2009. ISBN: 9783837420890

  25. Niss O, Chonat S, Dagaonkar N et al.: Genotype-phenotype correlations in hereditary elliptocytosis and hereditary pyropoikilocytosis, Blood Cells Mol Dis 61:4-9, 2016. DOI:10.1016/j.bcmd.2016.07.003

  26. Marchetti M, Quaglini S, Barosi G: Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis: analyzing the decision in different clinical scenarios. J Intern Med 244:217-226,1998. DOI:10.1046/j.1365-2796.1998.00362.x

  27. Schilling RF: Risks and benefits of splenectomy versus no splenectomy in hereditary spherocytosis - a personal view. Brit J Haematol 145:728-723, 2009. DOI:10.1111/j.1365-2141.2009.07694.x

  28. Bader-Meunier B, Gauthier F, Archambaud F et al.: Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 97:399-403, 2001. DOI:10.1182/blood.V97.2.399

  29. Stoehr GA, Sobh JN, Luecken J, et al.: Near-total splenectomy for hereditary spherocytosis: clinical prospects in relation to disease severity. Br J Haematol 132:791-793, 2006. DOI:10.1111/j.1365-2141.2005.05956.x

  30. Tripodi SI, Shamberger RC, Heeney MM, Tubman VN: Clinical and laboratory outcomes following total or partial splenectomy in patients with hereditary spherocytosis. Pediatr Hematol Oncol 26:1-8, 2019. DOI:10.1080/08880018.2019.1637983

  31. Englum BR, Rothman J, Leonard S et al. for the Splenectomy in Congenial Hemolytic Anemia Consortium. Hematologic outcomes after total splenectomy and partial splenectomy for congenital hemolytic anemia. J Pediatr. Surg 51:122-127, 2016. DOI:10.1016/j.jpedsurg.2015.10.028

  32. Guizetti L: Total versus partial splenectomy in pediatric hereditary spherocytosis: A systematic review and meta-analysis. Pediatr. Blood Cancer 63:1713-1722, 2016. DOI:10.1002/pbc.26106

10[Kapitel nicht relevant]

11[Kapitel nicht relevant]

12[Kapitel nicht relevant]

13[Kapitel nicht relevant]

14[Kapitel nicht relevant]

15Authors' Affiliations

Prof. Dr. med. Bernhard Wörmann
Amb. Gesundheitszentrum der Charité
Campus Virchow-Klinikum
Med. Klinik m.S. Hämatologie & Onkologie
Augustenburger Platz 1
13344 Berlin
Prof. Dr. med. Stefan Eber
Schwerpunktpraxis Pädiatrische
Hämatologie/Onkologie und
Kinderklinik der TU München
Waldfriedhofstr. 738
81377 München
PD Dr.med. Jeroen Goede
Medizinische Onkologie und Hämatologie
Kantonsspital Winterthur
Brauerstr. 15
8401 Winterthur
Dr. Anette Hoferer
Robert-Bosch-Krankenhaus
Auerbachstr. 110
70376 Stuttgart
Prof. Dr. med. Hubert Schrezenmeier
Universitätsklinikum Ulm
Institut für klinische Transfusionsmedizin
Helmholtzstr. 10
89081 Ulm
Univ.-Prof. Dr. Christian Sillaber
Allgemeines Krankenhaus Wien
Klinik für Innere Medizin I
Klinische Abt. für Hämatologie
und Hämostaseologie
Währinger Gürtel 18-20
A-1090 Wien

16Disclosures

according to the rules of the responsible Medical Societies.

16Disclosures

Comments